지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2022.7
- 수록면
- 894 - 906 (13page)
- DOI
- 10.4143/crt.2021.854
이용수
초록· 키워드
오류제보하기
Purpose This study aimed to explore the genomic and transcriptomic landscape of bladder cancer (BC) and its implication for treatment with an immune checkpoint inhibitor (ICI).Materials and Methods We analyzed whole-exome and -transcriptome sequences of tumor samples from 64 BC patients who underwent surgical resection with either transurethral resection or radical cystectomy. For exploratory purposes, programmed death-ligand 1 (PD-L1) expression was evaluated in a subset of patients (n=57) including those treated with ICI (n=8).Results We identified frequent molecular dysregulations in chromatin regulatory genes (<i>KDM6A, ARID1A, MLL2,</i> and <i>STAG2</i>) and recurrent copy number alterations. Thirty-five samples (54.7%) were PD-L1?positive (PD-L1 combined positive score ≥ 1) with a significantly higher exonic tumor mutational burden (TMB) compared to PD-L1?negative BC samples (p=0.010). We observed that various immune-responsive pathways, including the PD-L1 signaling pathway, were enriched significantly in PD-L1?positive BCs. Interestingly, genes in the CTLA4 pathway were enriched significantly in PD-L1?positive BC as well. Among eight patients who received ICI, progressive disease was confirmed in one patient, whose tumor had low exonic TMB, negative PD-L1 status, and a relatively colder microenvironment.Conclusion Gaining new insights into the molecular landscape of BC will improve treatment strategies. Our analysis suggests a rationale for studying dual checkpoint inhibition against BC.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Peripheral Blood Immune Cell-based Biomarkers in Anti-PD-1/PD-L1 Therapy
Immune Network
2020 .02
-
Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Cancer Research and Treatment
2017 .01
-
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
Journal of Pathology and Translational Medicine
2019 .01
-
Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy
Immune Network
2016 .04
-
PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
Journal of Pathology and Translational Medicine
2017 .01
-
Advantages of robotic PD over laparoscopic PD
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
Metformin Suppresses Both PD-L1 Expression in Cancer Cells and Cancer-Induced PD-1 Expression in Immune Cells to Promote Antitumor Immunity
Annals of Laboratory Medicine
2024 .09
-
Dysphagia Requiring Medical Attention in Parkinson’s Disease: A Korean Population-Based Study
Journal of Korean Medical Science
2023 .04
-
PD-1: A Negative Regulator of Phagocytosis by Tumour-Associated Macrophages in Colon Cancer
JOURNAL OF BACTERIOLOGY AND VIROLOGY
2019 .12
-
Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
Cancer Research and Treatment
2016 .01
-
A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset
Cancer Research and Treatment
2020 .01
-
Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment
생체재료학회지
2023 .03
-
Clinical Implication of High Sensitivity C-Reactive Protein for the Development of Dementia in Parkinson’s Disease
Dementia and Neurocognitive Disorders(대한치매학회지)
2015 .01
-
Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model
Investigative and Clinical Urology
2023 .01
-
Changes in Epidemiological Trends and Rehabilitation Usage in Neurological Diseases in Korea: Parkinson's Disease
뇌신경재활
2021 .01
-
Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors
Immune Network
2020 .06
-
Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation
Journal of Pathology and Translational Medicine
2021 .01
-
Interpretation of PD-L1 expression in gastric cancer: summary of a consensus meeting of Korean gastrointestinal pathologists
Journal of Pathology and Translational Medicine
2024 .05
-
Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
Cancer Research and Treatment
2022 .04
-
Development of genetically humanized PD-1 mice capable of evaluating preclinical studies of PD-1 immuno-oncology agents
한국실험동물학회 학술발표대회 논문집
2020 .07
이 논문의 저자 정보
최근 본 자료
댓글(0)
0